{Reference Type}: Journal Article
{Title}: FD-1050@NPs-cRGD: A novel NIR-II fluorophore for triple-negative breast cancer imaging.
{Author}: Fan H;Wu W;Chen Z;Zhu Q;Sun X;
{Journal}: Bioorg Med Chem Lett
{Volume}: 82
{Issue}: 0
{Year}: 02 2023 15
{Factor}: 2.94
{DOI}: 10.1016/j.bmcl.2023.129153
{Abstract}: Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive disease that is prone to metastasis and recurrence. It accounts for 15-20% of all breast cancer cases. Surgical resection is effective in removing most of the malignant tissues for non-metastasized tumors; however, some residual tumor tissues would be left, leading to a poor prognosis. Thus, real-time monitoring of surgical resection would be beneficial for the surgical resection of tumors. Although NIR-II fluorescent probe-guided surgical resection has been widely used for other types of diseases, it is not currently used for TNBC in clinical practice. Here, we describe the design and synthesis of a novel NIR-II fluorescent probe, FD-1050@NPs-cRGD, that targets TNBC. We found that it has a high fluorescence quantum efficiency, good stability, and low cytotoxicity. In vivo imaging in mice demonstrated a high tumor signal/normal tissue signal ratio, indicating that FD-1050@NPs-cRGD has great potential to be applied in tumor imaging of TNBC.